24-Hour Ambulatory BP: Which Tests to Order Alongside for Women

What 24-Hour Ambulatory BP Actually Measures

ABPM captures your blood pressure automatically every 20 to 30 minutes throughout a full day and night. A single office reading is a snapshot. ABPM is the film reel. It reveals your true 24-hour mean, your daytime mean, your nighttime mean, and, critically, whether you are a "dipper."

Dipper vs. Non-dipper: why it matters for women

A normal physiologic pattern is for blood pressure to fall 10 to 20 percent during sleep. This is called dipping. When that overnight drop is absent (a non-dipping pattern, defined as <10% nocturnal fall), cardiovascular risk rises substantially. Data from the International Database on Ambulatory blood pressure monitoring In relation to Cardiovascular Outcomes (IDACO) showed that non-dippers had a significantly higher risk of cardiovascular events independent of 24-hour mean BP.

Women with obstructive sleep apnea, PCOS, or late-stage perimenopause are disproportionately likely to be non-dippers. Sleep fragmentation from hot flashes is a direct contributor. That connection is one reason ABPM is clinically richer for women than a morning office reading.

Normal ranges: what the numbers mean for you

The 2017 American College of Cardiology/American Heart Association hypertension guideline defines these thresholds for ABPM:

| Period | Normal | Stage 1 HTN | |---|---|---| | 24-hour mean | <130/80 mmHg | 130/80 or higher | | Daytime (awake) | <135/85 mmHg | 135/85 or higher | | Nighttime (asleep) | <120/70 mmHg | 120/70 or higher |

Pregnancy uses different cut-offs. See the dedicated section below.

Masked hypertension: the pattern women underestimate

Masked hypertension means your office reading is normal but your ABPM average is elevated. A meta-analysis of 11 cohort studies published in the Journal of the American Medical Association found that masked hypertension carries a cardiovascular risk nearly equal to sustained hypertension. Women are at particular risk post-menopause and in the setting of PCOS-driven insulin resistance, because both conditions raise sympathetic tone preferentially at night.

Why Paired Labs Are Non-Negotiable

An elevated ABPM result is a signal, not a diagnosis. You need labs to answer three questions: What organ system is driving this? What has already been damaged? And which conditions common in women are either causing or worsening it?

Ordering ABPM without any labs is like reading a fire alarm and not checking which room is burning.

The core panel: what every woman needs

These six tests are appropriate regardless of life stage when ABPM shows elevated readings or a non-dipping pattern.

1. Comprehensive metabolic panel (CMP) Serum creatinine, estimated GFR, electrolytes, and liver enzymes. Renal function is both a cause and a consequence of hypertension. Hypokalemia on CMP raises immediate suspicion for primary aldosteronism.

2. Spot urine albumin-to-creatinine ratio (uACR) The uACR detects early renal damage before creatinine rises. The American Diabetes Association 2024 Standards of Care recommend uACR screening in anyone with hypertension and diabetes or at high metabolic risk. A uACR above 30 mg/g changes both treatment urgency and drug selection (favoring RAAS blockade). Women with a history of preeclampsia are at 4-fold higher lifetime risk of CKD, making uACR especially useful in this group.

3. Fasting lipid panel Cardiovascular risk stratification cannot be done without a lipid panel. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease uses non-HDL cholesterol as a primary risk marker. Women have a distinctive lipid trajectory: HDL typically falls and LDL rises sharply in the first 12 to 24 months after the final menstrual period.

4. Thyroid-stimulating hormone (TSH) Both hypothyroidism and hyperthyroidism alter BP. Hypothyroidism raises diastolic pressure through increased peripheral vascular resistance. Hyperthyroidism raises systolic pressure and heart rate. Subclinical hypothyroidism affects roughly 10% of women over 40, and postpartum thyroiditis peaks between 4 and 8 months after delivery. The American Thyroid Association 2014 guidelines recommend TSH in any woman with new or worsening hypertension and symptoms of thyroid dysfunction.

5. Fasting glucose and fasting insulin (with HOMA-IR) Insulin resistance raises BP through renal sodium retention and sympathetic nervous system activation. Fasting insulin is not part of a standard CMP and must be ordered separately. The HOMA-IR (homeostasis model assessment of insulin resistance) is calculated as fasting insulin (mcIU/mL) multiplied by fasting glucose (mg/dL), divided by 405. A HOMA-IR above 2.5 suggests clinically significant insulin resistance in women.

6. Aldosterone-to-renin ratio (ARR) Primary aldosteronism is the most common secondary cause of hypertension, affecting an estimated 5 to 10% of all hypertensive patients and a higher proportion of those with resistant or early-onset hypertension. Women with PCOS, adrenal incidentalomas, or hypokalemia on CMP should have an ARR drawn in the morning after 5 to 15 minutes of seated rest. Oral contraceptive pills, particularly those with drospirenone, affect aldosterone physiology and should be noted on the lab requisition.

Life-Stage Panels: Tailoring the Work-Up by Where You Are

Your hormonal status changes what is most likely driving an abnormal ABPM, and it changes which labs to prioritize.

Reproductive years (ages 18 to 40, not currently pregnant)

If you are in your reproductive years and have ABPM-detected hypertension or a non-dipping pattern, the most important considerations are PCOS, primary aldosteronism, renal artery stenosis (fibromuscular dysplasia is most common in women under 50), and stimulant or decongestant use.

Add to the core panel:

• Free and total testosterone
• DHEA-S
• SHBG
• LH and FSH (if cycle irregularity is present)
• HbA1c

PCOS affects an estimated 8 to 13% of women of reproductive age and is independently associated with a 2 to 3 mmHg higher daytime ambulatory BP compared to BMI-matched controls, driven largely by insulin resistance and androgen excess. The connection is underappreciated in primary care settings.

If you are on combined oral contraceptives and your ABPM shows a non-dipping pattern or elevated 24-hour mean, that is a known pill effect. Estrogen-containing pills raise angiotensinogen, which can increase BP in susceptible women. Switching to a progestin-only method or non-hormonal contraception is worth discussing with your clinician.

Trying to conceive or actively planning pregnancy

If ABPM shows sustained daytime readings at or above 135/85 mmHg before conception, that needs to be addressed before pregnancy. Chronic hypertension is associated with a significantly higher risk of superimposed preeclampsia, preterm birth, and placental abruption.

Add to the core panel:

• Urine protein (24-hour or spot uACR)
• Anti-phospholipid antibody panel (lupus anticoagulant, anticardiolipin, anti-beta2-glycoprotein I): antiphospholipid syndrome causes both hypertension and pregnancy loss
• Fasting glucose and HbA1c
• TSH with free T4

Pregnancy and postpartum

This is addressed in full in the section below.

Perimenopause (roughly ages 40 to 55, irregular cycles)

Perimenopause is when masked hypertension becomes most likely to appear without explanation. Estrogen withdrawal raises central sympathetic activity, reduces nitric oxide bioavailability, and promotes arterial stiffening. Night sweats fragment sleep, blunting the normal overnight BP dip. A study in the journal Menopause found that the prevalence of masked hypertension in perimenopausal women was approximately 20% higher than in premenopausal controls.

Add to the core panel:

• FSH and estradiol (to confirm menopausal transition stage)
• hs-CRP (inflammatory cardiovascular risk marker)
• Vitamin D 25-OH (deficiency is common and associated with non-dipping)
• Sleep study referral (or validated questionnaire for OSA risk): non-dipping pattern warrants active sleep apnea screening

Post-menopause

After the final menstrual period, cardiovascular risk in women accelerates rapidly. The protective effect of endogenous estrogen on endothelial function is largely gone. BP variability on ABPM becomes a stronger predictor of stroke in this group.

Add to the core panel:

• Full thyroid panel (TSH, free T4, free T3)
• hs-CRP and lipoprotein(a)
• Fasting lipids with particle sizing if available
• DEXA scan referral (hypertension is independently associated with osteoporosis; both share common inflammatory and vascular mechanisms)

The table below summarizes the add-on labs by life stage for quick clinical reference.

| Life Stage | Core Panel | Add-On Tests | |---|---|---| | Reproductive years | CMP, uACR, lipids, TSH, fasting glucose/insulin, ARR | Free testosterone, DHEA-S, SHBG, HbA1c | | TTC / pre-conception | As above | Anti-phospholipid panel, TSH/free T4, 24-hr urine protein | | Perimenopause | As above | FSH, estradiol, hs-CRP, vitamin D, OSA screen | | Post-menopause | As above | Full thyroid panel, hs-CRP, lipoprotein(a), DEXA referral |

Pregnancy and Postpartum: ABPM and Safety Guidance

Hypertensive disorders affect 10 to 15% of pregnancies and are a leading cause of maternal mortality in the United States. ABPM is increasingly used in pregnancy precisely because white-coat effects are common during prenatal visits, and because the nighttime dipping pattern carries prognostic meaning that office readings cannot provide.

ABPM thresholds in pregnancy

The American College of Obstetricians and Gynecologists (ACOG) 2019 Gestational Hypertension and Preeclampsia practice bulletin defines hypertension in pregnancy as systolic BP at or above 140 mmHg or diastolic at or above 90 mmHg on two readings at least 4 hours apart. For ABPM, a daytime mean above 135/85 mmHg or a nighttime mean above 120/70 mmHg warrants the same clinical urgency.

Non-dipping in the second trimester is an early sign of impending preeclampsia, often appearing weeks before proteinuria or edema develop.

Labs to order with ABPM in pregnancy

• 24-hour urine protein (or spot uACR)
• Complete blood count (to detect thrombocytopenia, a preeclampsia marker)
• Liver enzymes (AST, ALT) and uric acid
• Serum creatinine
• Blood glucose and HbA1c (gestational diabetes and hypertension frequently co-occur)
• Anti-phospholipid antibody panel if pre-term or recurrent loss history exists

Antihypertensive medications in pregnancy carry significant restrictions. Methyldopa, nifedipine (extended release), and labetalol are the most studied and generally accepted first-line options in pregnancy. ACE inhibitors and ARBs are contraindicated in pregnancy from the second trimester onward due to fetal renal toxicity and must be discontinued before conception if possible. Women on ACE inhibitors who are contemplating pregnancy should discuss transition plans well in advance.

Postpartum and lactation

BP often spikes in the first week postpartum even in women with no antenatal hypertension. ABPM in the postpartum period helps distinguish postpartum preeclampsia (which can present up to 6 weeks after delivery) from new-onset essential hypertension.

If antihypertensive therapy is needed while breastfeeding, nifedipine and labetalol are considered compatible with lactation by LactMed (NIH). ACE inhibitors such as enalapril transfer into breast milk at low levels and are generally considered acceptable, but the data remain limited. Aldosterone antagonists such as spironolactone have limited lactation data and are generally avoided until weaning.

Postpartum thyroiditis peaks at 4 to 8 months after delivery and can cause both hypo- and hyperthyroid phases, each altering BP. A TSH at 6 to 8 weeks postpartum is worth ordering alongside any ABPM interpretation in this window.

How to Lower an Elevated 24-Hour Ambulatory BP

Treatment depends entirely on the cause uncovered by paired labs. There is no single answer, but the framework below covers the most common findings in women.

When insulin resistance is the driver

Dietary carbohydrate reduction and aerobic exercise reduce sympathetic tone and lower 24-hour mean BP. A randomized controlled trial published in JAMA showed that a Mediterranean-style diet reduced systolic BP by approximately 3 mmHg over 12 months. For women with PCOS and HOMA-IR above 2.5, metformin may reduce insulin-driven BP elevation as a secondary benefit.

When primary aldosteronism is confirmed

Spironolactone (a mineralocorticoid receptor antagonist) is first-line medical therapy for bilateral adrenal hyperplasia. In women of reproductive age, spironolactone has antiandrogen properties that may benefit PCOS-related symptoms simultaneously. The dose range is typically 25 to 100 mg daily. Spironolactone is teratogenic and requires reliable contraception in women who could become pregnant.

When thyroid dysfunction is the driver

Treating the underlying thyroid disorder generally normalizes BP. This means levothyroxine for hypothyroidism and appropriate anti-thyroid therapy for hyperthyroidism. Target TSH within the age-appropriate range before attributing residual hypertension to a separate cause.

When menopause-related vascular changes are the driver

The Menopause Society's 2022 position statement on menopausal hormone therapy (MHT) notes that transdermal estradiol does not raise BP and may have a modest antihypertensive effect compared to oral estrogen, which raises angiotensinogen. For women in early menopause (within 10 years of final menstrual period) who have no contraindications, MHT with transdermal estradiol should be considered as part of the cardiovascular risk conversation, not dismissed as irrelevant to BP management.

Non-pharmacologic measures with good evidence in perimenopausal and postmenopausal women include:

• Sodium restriction to under 2,300 mg per day (per AHA 2021 dietary guidelines)
• Resistance training at least 2 days per week (lowers systolic BP by 3 to 5 mmHg on ABPM in post-menopausal women per a meta-analysis in the British Journal of Sports Medicine)
• Sleep hygiene and OSA treatment (CPAP use reduces nighttime BP by 3 to 6 mmHg in confirmed non-dippers)

How to Raise a Low 24-Hour Ambulatory BP

A 24-hour mean below 100/60 mmHg (orthostatic symptoms present) or a pattern of symptomatic daytime hypotension warrants its own work-up. Low ABPM is less commonly discussed but matters for women, who are more likely to experience orthostatic hypotension during pregnancy and in older age on antihypertensive medications.

Labs to consider when ABPM reads low:

• Cortisol (morning, 8 a.m.) and ACTH stimulation test if adrenal insufficiency is suspected
• Sodium, potassium, and renin (to detect salt-wasting states)
• TSH (hypoadrenalism and hypothyroidism can both depress BP)
• Hemoglobin and ferritin (anemia in women of reproductive age is common and frequently overlooked as a BP-depressing factor)

Symptomatic low ABPM in a woman on antihypertensives is often an over-treatment signal. Dose reduction or agent change is the first step before ordering an extensive secondary work-up.

Who This Is Right For, and Who Should Wait

Good candidates for ABPM with a full paired-lab panel

• Women with white-coat hypertension (elevated office readings, anxiety about clinical settings)
• Women with PCOS or insulin resistance and any elevated office reading
• Women in perimenopause or post-menopause with new or worsening BP readings
• Any woman with hypokalemia on routine labs (rules out primary aldosteronism)
• Women with a history of preeclampsia (masked HTN risk is significantly elevated in this group)
• Women with a non-dipping pattern on a prior ABPM
• Pregnant women with office readings consistently at the borderline (130 to 139 / 80 to 89 mmHg)

Situations where ABPM should wait or is less useful

• Atrial fibrillation or highly irregular heart rhythm: oscillometric ABPM devices are inaccurate in this setting
• Arm circumference requiring a thigh or wrist cuff: validate the device for your cuff type before ordering
• Active skin conditions or lymphedema of the monitored arm

A note on the evidence gap

Most landmark ABPM outcome trials enrolled predominantly male or male-majority cohorts. The IDACO database, which drives many current thresholds, included women but did not always report sex-stratified results in its earliest publications. The specific nighttime BP thresholds defining non-dipping risk in women across hormonal life stages are incompletely studied. What is extrapolated from mixed-sex data: the 10% nocturnal dip threshold and the specific cardiovascular event risk ratios. What is directly studied in women: the association between masked hypertension and preeclampsia history, and the higher prevalence of white-coat hypertension in women compared to men.

This evidence gap is why paired labs matter so much. When the outcome thresholds are uncertain, understanding the mechanism is your best guide to treatment.